As a customer-driven service company, we offer pharmaceutical clients comprehensive skills, ranging from process development, analytical method development, radiolabeling, cGMP- compliant scale-up and manufacturing of active ingredients, as well as regulatory support.
Girindus is the only company providing expertise in both oligonucleotide and small molecule API’s, combined with the unique offering of radioactive labelling.We operate commercial scale oligonucleotide production at our FDA registered and inspected site in Cincinnati, Ohio, USA, which is also home to our laboratories and pilot plant facilities.
|2010||Focus on oligonucleotides further strengthened|
|2009||Completion of Oligonucleotides capacity expansion|
|2008||Girindus sells activities in Kuensebeck|
|2005||Solvay acquires majority stake in Girindus|
|2001||Girindus acquires manufacturing site in Cincinnati, Ohio, USA from Aventis|
|2000||IPO - Listing “Neuer Markt” Frankfurt, Germany|
|1999||Acquisition of API production facilities in Kuensebeck, Germany|
|1986||Girindus USA is established|
|1975||Girindus Germany and Switzerland are founded as independent service providers to the pharmaceutical industry|
Today, over 70 associates work for Girindus worldwide.